Cargando…
The Impact of Label Changes (Boxed Warning) on Real-World Febuxostat Utilization in Patients with Gout: A Cross-Sectional Drug Utilization Study
INTRODUCTION: This drug utilization study evaluated the impact of 2019 label changes on real-world febuxostat utilization among patients with gout. We describe the numbers and proportions of patients initiating febuxostat as new users (allopurinol-naïve) or prevalent new users (prior allopurinol use...
Autores principales: | Sosinsky, Alexandra Z., Song, Yufei, Gunawardhana, Lhanoo, Phillips, Syd, Page, Matt |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469119/ https://www.ncbi.nlm.nih.gov/pubmed/37460856 http://dx.doi.org/10.1007/s40744-023-00581-x |
Ejemplares similares
-
Effects of Febuxostat in Early Gout: A Randomized, Double‐Blind, Placebo‐Controlled Study
por: Dalbeth, Nicola, et al.
Publicado: (2017) -
Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study
por: Gunawardhana, Lhanoo, et al.
Publicado: (2018) -
Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo‐Controlled Study
por: Saag, Kenneth G., et al.
Publicado: (2018) -
Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial
por: Saag, Kenneth G., et al.
Publicado: (2022) -
Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo‐Controlled Study
por: Gunawardhana, Lhanoo, et al.
Publicado: (2017)